

1 ENGROSSED SENATE  
2 BILL NO. 1464

By: Hicks, Montgomery, and  
Garvin of the Senate

3 and

4 Strom, Munson, and Ranson  
5 of the House

6  
7 An Act relating to public health; amending 63 O.S.  
8 2021, Section 1-533, which relates to educational and  
9 newborn screening programs; requiring list of  
10 disorders to be identical to the federal Recommended  
11 Uniform Screening Panel to extent practicable; and  
12 providing an effective date.

13 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

14 SECTION 1. AMENDATORY 63 O.S. 2021, Section 1-533, is  
15 amended to read as follows:

16 Section 1-533. A. The State Commissioner of Health shall  
17 provide, pursuant to the provisions of Section 1-534 of this title,  
18 as technologies and funds become available, an intensive educational  
19 and newborn screening program among physicians, hospitals, public  
20 health nurses, and the public concerning phenylketonuria, related  
21 inborn metabolic disorders, and other genetic or biochemical  
22 disorders for which:

23 1. Newborn screening will provide early treatment and  
24 management opportunities that might not be available without  
screening; and

1           2. Treatment and management will prevent intellectual  
2 disabilities and/or reduce infant morbidity and mortality.

3           B. This educational and newborn screening program shall include  
4 information about:

5           1. The nature of the diseases;

6           2. Examinations for the detection of the diseases in infancy;  
7 and

8           3. Follow-up measures to prevent the morbidity and mortality  
9 resulting from these diseases.

10          C. For purposes of this section, "phenylketonuria" means an  
11 inborn error of metabolism attributable to a deficiency of or a  
12 defect in phenylalanine hydroxylase, the enzyme that catalyzes the  
13 conversion of phenylalanine to tyrosine. The deficiency permits the  
14 accumulation of phenylalanine and its metabolic products in the body  
15 fluids. The deficiency can result in intellectual disabilities  
16 (phenylpyruvic oligophrenia), neurologic manifestations (including  
17 hyperkinesia, epilepsy, and microcephaly), light pigmentation, and  
18 eczema. The disorder is transmitted as an autosomal recessive trait  
19 and can be treated by administration of a diet low in phenylalanine.

20          D. To the extent practicable, the list of disorders screened  
21 for under this section shall be identical to the Recommended Uniform  
22 Screening Panel of the United States Department of Health and Human  
23 Services.

24

